Interventional Cardiology Fellows
Cameron Dowling, MBBS, PhD
Dr.
Dowling is an Australian cardiology fellow currently undertaking interventional
training at Stanford. He undertook medical training at the University of
Adelaide, South Australia before completing his general cardiology fellowship
at St Vincent’s Hospital, Sydney. Dr Dowling then completed a PhD at the University
of London, where he developed, validated, and described the first‐in‐human
experience of a computer model of TAVR in bicuspid aortic valve. He then
undertook coronary and structural interventional cardiology training at
MonashHeart, Melbourne. Dr Dowling is an emerging opinion leader in the field
of TAVR and is frequently invited to speak at international conferences. He is
the recipient of numerous national and international research awards, including
the BCIS Young Investigator Award and the CRT Young Leadership Award. He is the
principal investigator on several trials evaluating the application of computer
modelling to TAVR procedures. Dr Dowling wishes to pursue a clinical and
academic career in coronary and structural intervention, with an interest in
computational modelling and investigational devices. When outside of the cath
lab, he enjoys reading, bicycle riding and piano.
Maggie Ning, MD, PharmD
Dr. Ning was born in China, but she grew up
mostly in Texas. She went to the University of Texas at Austin for undergrad
and received her PharmD degree at the College of Pharmacy. She received her MD
degree from UT Southwestern Medical Center and moved to California for Internal
Medicine residency at Stanford. Dr. Ning plans to continue her training as a
cardiology fellow at Stanford. She is passionate about both cardiology and
oncology and thoroughly enjoys taking care of these patient populations.
Subsequently, she has completed several research projects and publications in
both fields. She hopes to combine her clinical and research interests by
contributing to the growth of the field of cardio-oncology. She hopes she can
also use her pharmacology background to better understand the complex pharmacokinetics
and pharmacodynamics involving oncology therapies and cardiotoxicity. She is
particularly interested in the role of noninvasive imaging to help identify
these patients that may be at risk for cardiotoxicity.